Design, conduct, and analysis of a multicenter, pharmacogenomic, biomarker study in matched patients with severe sepsis treated with or without drotrecogin Alfa (activated)

被引：0
作者：
Djillali Annane
Jean Paul Mira
Lorraine B Ware
Anthony C Gordon
Jonathan Sevransky
Frank Stüber
Patrick J Heagerty
Hugh F Wellman
Mauricio Neira
Alexandra DJ Mancini
James A Russell
机构：
[1] Hopital R. Poincare (AP-HP),Service de reanimation medicale, CIC
[2] Cochin Hotel-Dieu University Hospital Medical Intensive Care Unit,IT805 (INSERM)
[3] AP-HP,Université Paris Descartes, Sorbonne Paris Cité
[4] Vanderbilt University School of Medicine,Allergy, Pulmonary and Critical Care Medicine
[5] Charing Cross Hospital,Section of Anaesthetics, Pain Medicine, and Intensive Care, Imperial College London
[6] MICU,Department of Biostatistics
[7] John Hopkins BMC,Critical Care Research Laboratories, The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research
[8] Universitatsklinik fur Anasthesiologie und Schmerztherapie Inselspital,Hospital Raymond Poincaré (AP
[9] University of Washington,HP)
[10] Sirius Genomics Inc,undefined
[11] St. Paul’s Hospital and University of British Columbia,undefined
[12] University of Versailles SQY,undefined
来源：
Annals of Intensive Care | / 2卷
关键词：
Drotrecogin alfa (activated); Pharmacogenomics biomarker; Predictive marker; Propensity score; Severe sepsis; Treatment selection; Sepsis; Drotrecogin alfa activated (DAA); Activated protein C; Genome wide association study; Survival;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 234 条
[1]  
Angus DC(2001)Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care Crit Care Med 29 1303-1310
[2]  
Linde-Zwirble WT(2001)Severe sepsis: a European estimate of the burden of disease in ICU [oral presentation abstract from 14th Annual Congress of the European Society of Intensive Care Medicine, Geneva, Switzerland, 30 September-3 October 2001] Intensive Care Med 27 S284-1554
[3]  
Lidicker J(2003)The epidemiology of sepsis in the United States from 1979 through 2000 N Engl J Med 348 1546-709
[4]  
Clermont G(2001)Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group. Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 344 699-1034
[5]  
Carcillo J(2002)Assessing the use of activated protein C in the treatment of severe sepsis N Engl J Med 347 1030-1341
[6]  
Pinsky MR(2005)Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death N Engl J Med 353 1332-843
[7]  
Davies A(2007)Researching Severe Sepsis and Organ Dysfunction in Children: A Global Perspective (RESOLVE) Study Group Lancet 369 836-1197
[8]  
Green C(2008)International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy Curr Med Res Opin 24 1187-1947
[9]  
Hutton J(2008)Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock Intensive Care Med 34 1935-1153
[10]  
Martin GS(2011)Genomics and drug response N Engl J Med 364 1144-887
12345678910